-
公开(公告)号：US20230357415A1
公开(公告)日：2023-11-09
申请号：US18024143
申请日：2021-09-10
Inventor： Yong Sung KIM , Hae-Sim PARK , Jung Eun KIM , Keunok JUNG , Dong-Hyun LEE
IPC: C07K16/28
CPC classification number: C07K16/2866 , C07K2317/31 , C07K2317/30 , C07K2317/622 , C07K2317/92 , C07K2317/24 , C07K2317/732 , C07K2317/35 , C07K2317/522 , C07K2317/526
Abstract: An IL-4Rα×IL-5Rα bispecific antibody that simultaneously binds to interleukin (IL)-4 receptor a (IL-4Rα, CD124) and IL-5 receptor a (IL-5Rα, CD125) is provided. A multispecific antibody including the bispecific antibody, a nucleic acid encoding the bispecific antibody or multispecific antibody, a vector including the nucleic acid, and cells transformed by the vector are disclosed. Additionally, a method for producing the bispecific antibody and therapeutic uses of the multispecific antibody in preventing or treating allergic diseases, inflammatory diseases, and eosinophilic diseases associated with IL-4, IL-13 and/or IL-5 are disclosed.
-
公开(公告)号：US20190062375A1
公开(公告)日：2019-02-28
申请号：US16081342
申请日：2017-03-28
Inventor： Yong Sung KIM , Ye Jin KIM
IPC: C07K7/08 , C07K16/28 , A61K39/395 , A61K38/17 , A61K38/08
Abstract: The present invention relates to methods of overcoming the resistance to an EGFR (Epidermal Growth Factor Receptor)-targeting antibody through a peptide that binds specifically to neuropilin-1 (NRP1). Moreover, the present invention relates to a fusion antibody in which a peptide that binds specifically to NRP1 is fused to an EGFR-targeting antibody, and to a composition of overcoming the resistance to an EGFR-targeting antibody alone by co-administration of the EGFR-targeting antibody and an NRP1-binding peptide-fused Fc. In addition, the fusion antibody according to the present invention, in which the NRP1-specific binding peptide is fused to an EGFR-targeting antibody, overcomes the resistance to the EGFR-targeting antibody alone in pancreatic cancer. Furthermore, the fusion antibody, in which the NRP1-specific binding peptide is fused to the EGFR-targeting antibody, also overcomes resistance to the EGFR-targeting antibody alone even in lung cancer. Thus, the NRP1-specific binding-fused EGFR-targeting antibody according to the present invention may be highly effective in the treatment of various tumors resistant to EGFR-targeting antibody alone.
-
3.发明申请公开(公告)号：US20180051064A1
公开(公告)日：2018-02-22
申请号：US15560232
申请日：2016-03-23
Inventor： Yong Sung KIM , Ye Jin KIM
IPC: C07K14/705 , A61K9/127 , G01N33/574 , G01N33/68
CPC classification number: C07K14/705 , A61K9/127 , A61K38/00 , A61K47/50 , C07K19/00 , C07K2317/52 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/55 , C07K2317/56 , C07K2317/622 , C07K2319/30 , G01N33/53 , G01N33/57492 , G01N33/6845 , G01N33/6872 , G01N33/6893 , G01N2333/70596 , G01N2800/7014
Abstract: A peptide that binds specifically to neuropilin-1 (NRP1) without binding to neuropilin-2 (NRP2) is provided. A fusion protein, a fusion antibody, small-molecule drug, a nanoparticle, or a liposome, which comprises the peptide, and a pharmaceutical composition for treating or preventing cancer or angiogenesis-related diseases, and a composition for diagnosing cancer or angiogenesis-related diseases are provided. A polynucleotide encoding the peptide that binds specifically to NRP1 and a method for screening the peptide that binds specifically to NRP1 are provided. An antibody heavy-chain constant region Fc-fused peptide binding specifically to NRP1 has the property of binding specifically to NRP1, and thus when it is administered in vivo, it accumulates selectively in tumor tissue, and widens the intercellular space between tumor-associated endothelial cells to promote its extravasation and increases its tumor tissue penetration.
-
公开(公告)号：US20190218267A1
公开(公告)日：2019-07-18
申请号：US16329817
申请日：2017-08-31
Applicant: Korea University Research and Business Foundation , AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Inventor： Kyung-Mi LEE , Seon Ah LIM , Yong Sung KIM , Ye Jin KIM
Abstract: A heterodimeric Fc-fused protein and a pharmaceutical composition comprising the heterodimeric Fc-fused protein are disclosed. The heterodimeric Fc-fused protein comprises first and second Fc regions of an immunoglobulin heavy chain constant region (Fc) pair and in which IL-21 is bound to at least one of the N-terminus or the C-terminus of the first Fc region and/or the second Fc region, wherein CH3 domains of the first Fc region and the second Fc region are mutated such that the formation of a heterodimer is promoted.When the heterodimeric Fc-fused protein according to the present invention is used, an in vivo half-life of IL-21 included in the heterodimeric Fc-fused protein may be significantly increased.
-
5.发明申请公开(公告)号：US20180346600A1
公开(公告)日：2018-12-06
申请号：US15778966
申请日：2016-10-12
Inventor： Yong Sung KIM , Hye Ji CHOI , Ji Hee HA
CPC classification number: A61K39/395 , C07K16/46 , C12N15/81
Abstract: A method for evaluating and screening a mutant inducing the high-efficiency formation of heterodimers from a human antibody heavy chain constant region mutant pair combination library in order to increase the yield of formation of human antibody heterodimeric heavy chain constant regions. A heterodimeric heavy chain constant region (heterodimeric F) library is obtained by the method. A CH3 domain mutant pair, in which the formation of the heterodimeric heavy chain constant regions is preferred in the library, forms heterodimeric heavy chain constant regions at a high yield of at least 80-90%, and also has excellent thermal stability and retains binding ability to the heavy chain constant region receptor (FcRn).
-
Patent Agency Ranking
公开(公告)号：US20230416380A1
公开(公告)日：2023-12-28
申请号：US18025833
申请日：2021-09-10
Inventor： Yong Sung KIM , Hae-Sim PARK , Jung Eun KIM , Keunok JUNG , Dong-Hyun LEE
CPC classification number: C07K16/2866 , G01N33/6869 , A61P37/08 , G01N2333/7155 , C07K2317/24 , C07K2317/732 , G01N2800/24 , C07K2317/92 , C07K2317/34 , C07K2317/76 , C07K2317/73
Abstract: A humanized antibody or antigen-binding fragment thereof that binds to the human IL-5 receptor alpha subunit (IL-5Rα), which is a receptor of human interleukin-5 (IL-5); a nucleic acid encoding the antibody or antigen-binding fragment thereof; a vector containing the nucleic acid; and a cell transformed with the vector are disclosed. A method for producing the antibody or antigen-binding fragment thereof; a conjugate containing the antibody or antigen-binding fragment thereof; a bispecific or multispecific antibody containing the antibody or antigen-binding fragment thereof; and a composition thereof are disclosed. Also disclosed are methods for preventing or treating an allergic disease, an inflammatory disease and/or a disease caused by an increase in eosinophils; and for diagnosis of allergic diseases, inflammatory diseases, and/or diseases caused by an increase in eosinophils.
-
公开(公告)号：US20180237541A1
公开(公告)日：2018-08-23
申请号：US15944505
申请日：2018-04-03
Inventor： Yong Sung KIM , Hye Ji CHOI , Eun Sil SUNG
CPC classification number: C07K16/46 , A61K2039/505 , C07K16/00 , C07K16/2878 , C07K16/468 , C07K2317/31 , C07K2317/526 , C07K2317/622 , C07K2319/30
Abstract: Disclosed are a CH3 domain variant pair of an antibody, a method for preparing same, and a use thereof. A mutation is induced in the CH3 domain so as to improve a yield of forming a heterodimer heavy chain constant region of an antibody. The CH3 domain heterodimer forms a heterodimer heavy chain constant region with a high efficiency of 90 to 95% or more and also has outstanding heat stability. A heterodimer heavy chain constant region including the CH3 domain heterodimer can construct a bispecific monoclonal antibody which simultaneously recognizes two kinds of antigens. The CH3 domain heterodimer and the bispecific antibody or fusion protein of an antibody constant region comprising same can be usefully applied to the treatment or prevention of a disease associated with a target antigen or a target protein.
-
8.发明公开公开(公告)号：US20240352100A1
公开(公告)日：2024-10-24
申请号：US18290613
申请日：2022-07-20
Inventor： Yong Sung KIM , Dasom LEE , Jisu SEO , Hae Jin KWEON , Dae-Seong KIM
CPC classification number: C07K16/18 , C12N15/63 , C07K2317/14 , C07K2317/31 , C07K2317/565 , C07K2317/76 , C07K2317/77 , C07K2319/00
Abstract: A cell-penetrating degrading antibody is disclosed. In the cell-penetrating degrading antibody, U-Box of E3 that can bind to E2 of an ubiquitin-proteasome system (UPS), which is an intracellular protein degradation system, or an E3 recruiter (E3 recruiting ligand) that can bind to E3 of the UPS is fused to a cell-penetrating interfering antibody that penetrates into the cytosol of living cells and specifically recognizes a target protein. A composition containing the cell-penetrating antibody and uses thereof are disclosed.
-
公开(公告)号：US20230076637A1
公开(公告)日：2023-03-09
申请号：US17796788
申请日：2021-02-05
Inventor： Yong Sung KIM , Jeong-Ah KIM , Keunok JUNG , Seyoung LEE , Min-Jeong SON
IPC: C07K16/28 , C07K14/705 , C12N15/63 , A61K39/00
Abstract: The present invention relates to: a composition for delivering a viral antigen-derived CD8+ T cell antigen epitope or a peptide comprising same to the cytoplasm of a target cell to thereby present the epitope or peptide to major histocompatibility complex class I (MHC-1), which is an antigen-presenting molecule on the cell surface; a composition comprising same; and a use thereof.
-
公开(公告)号：US20230045418A1
公开(公告)日：2023-02-09
申请号：US17781931
申请日：2020-11-27
Inventor： Yong Sung KIM , Seyoung LEE
IPC: C07K16/28 , G01N33/574
Abstract: A TCR-like antibody or an antigen-binding fragment thereof, the antibody binding to and having specific and improved affinity to an MHC-I molecule, particularly a CMV pp65 peptide complex (CMVP495-503/HLA-A*02:01) presented by HLA-A*02 are disclosed. A nucleic acid for coding the TCR-like antibody or the antigen-binding fragment thereof; an expression vector containing the nucleic acid; a cell transformed to the expression vector; a method for producing same; a composition containing a T cell for expressing the antibody or the antigen-binding fragment thereof as a chimeric antigen receptor; uses of the composition in preventing or treating cancer or an infectious disease; uses of the composition in diagnosis; methods for preventing and/or treating cancer or infectious diseases; and methods for diagnosing are disclosed.
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.017 seconds)
